Teleflex reports Q2 adjusted EPS $3.73, consensus $3.37

Reports Q2 revenue $780.9M, consensus $771.53M. “We are pleased with our solid second quarter results, which reflected an increase in constant currency revenue growth and adjusted earnings per share compared to the prior year period,” said Liam Kelly, Teleflex’s (TFX) Chairman, President and Chief Executive Officer. “We continue to make progress in the ongoing execution of our value creation strategy across our business. We started the third quarter by successfully completing our acquisition of BIOTRONIK’s Vascular Intervention business, which drove the increase in our 2025 adjusted constant currency revenue guidance. Excluding the impact of the acquisition, our underlying adjusted constant currency revenue guidance for 2025 remains unchanged from our previously provided guidance. The addition of the Vascular Intervention business enhances our global presence in the cath lab with a broad portfolio of therapeutic products, which complement and expand our portfolio of interventional access products, and establish Teleflex’s global footprint in the fast-growing peripheral intervention market. As we look ahead, we remain focused on our work to unlock value through the separation of NewCo as we continue to actively explore options to maximize shareholder value creation.”